EUVIMEDEUVIMED entdecken
Crossref

4‐Methylumbelliferone Sensitizes Breast Cancer Spheroids to Chemotherapeutic Treatment With Epirubicin: New Perspectives for Pharmacological Repositioning

Daiana Luján Vitale iD, Antonella Icardi, Paolo Rosales, Candela Morán, Ina Sevic, Laura Daniela Alaniz iD

IUBMB Life · 2025

DOI: 10.1002/iub.70075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Daiana Luján Vitale und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Microambiente Tumoral - Centro de Investigaciones Básicas y Aplicadas (CIBA) - Universidad Nacional del Noroeste de la Provincia de Bu…. Hauptthemen laut MEDLINE: Breast Neoplasms, Hymecromone, Spheroids, Cellular, Epirubicin. Die Arbeit nennt 80 Literaturangaben. Gefördert von: Universidad Nacional del Noroeste de la Provincia de Buenos Aires, HORIZON-MSCA-2021-SE-01, Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemoresistance remains a significant hurdle in breast cancer treatment. To address this, we explored the therapeutic potential of combining epirubicin, an anthracycline commonly associated with the development of resistance in cancer cells and with known cytotoxic effects, with 4‐methylumbelliferone, a plant‐derived coumarin. Our results demonstrated a coactive enhancement of epirubicin efficacy when this combination was applied to 3D breast cancer models, irrespective of molecular subtype. Mechanistically, 4‐methylumbelliferone inhibits synthesis of hyaluronan, a key component of the tumor microenvironment that promotes tumor growth and metastasis. By disrupting hyaluronan production, this compound facilitated drug penetration into tumor spheroids and reduced the expression of drug efflux pumps, thereby increasing intracellular drug accumulation. Consequently, the combined treatment led to a significant reduction in cell viability and promotion of cell death. Our findings suggest that targeting hyaluronan metabolism in conjunction with conventional chemotherapy offers a promising strategy to overcome drug resistance in breast cancer. This drug repositioning approach not only improves treatment efficacy but also highlights the potential of targeting the tumor microenvironment to enhance cancer therapy. Further studies are warranted to elucidate the underlying mechanisms and to evaluate the clinical translation of this combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHymecromoneSpheroids, CellularEpirubicinDrug RepositioningHumansFemaleDrug Resistance, NeoplasmTumor MicroenvironmentHyaluronic AcidCell Line, TumorCell SurvivalDrug SynergismCell ProliferationTumor Cells, Cultured

Stichwörter der Autor:innen

4‐methylumbelliferonebreast cancerdrug repositioningepirubicinhyaluronan

Substanzen

HymecromoneEpirubicinHyaluronic Acid

Autor:innen und Institutionen

  • Laboratorio de Microambiente Tumoral - Centro de Investigaciones Básicas y Aplicadas (CIBA) - Universidad Nacional del Noroeste de la Provincia de Buenos Aires, Junín, Argentina.
  • Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires (CITNOBA) - UNNOBA-UNSAdA-CONICET, Junín, Argentina.

ORCID-Profile: Daiana Luján Vitale, Laura Daniela Alaniz

Förderung

  • Universidad Nacional del Noroeste de la Provincia de Buenos Aires
  • HORIZON-MSCA-2021-SE-01
  • Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación

Zitieren

APA

Vitale, D. L., Icardi, A., Rosales, P., Morán, C., Sevic, I., & Alaniz, L. D. (2025). 4‐Methylumbelliferone Sensitizes Breast Cancer Spheroids to Chemotherapeutic Treatment With Epirubicin: New Perspectives for Pharmacological Repositioning. IUBMB Life. https://doi.org/10.1002/iub.70075

Vancouver

Vitale DL, Icardi A, Rosales P, Morán C, Sevic I, Alaniz LD. 4‐Methylumbelliferone Sensitizes Breast Cancer Spheroids to Chemotherapeutic Treatment With Epirubicin: New Perspectives for Pharmacological Repositioning. IUBMB Life. 2025. doi:10.1002/iub.70075

BibTeX
@article{Vitale2025,
  author = {Vitale, Daiana Luján and Icardi, Antonella and Rosales, Paolo and Morán, Candela and Sevic, Ina and Alaniz, Laura Daniela},
  title = {4‐Methylumbelliferone Sensitizes Breast Cancer Spheroids to Chemotherapeutic Treatment With Epirubicin: New Perspectives for Pharmacological Repositioning},
  journal = {IUBMB Life},
  year = {2025},
  doi = {10.1002/iub.70075}
}
Kostenlos starten →